Good morning! This is Fly Charts, the daily charts-only newsletter from Gadfly; sign up here. From oil disunity to biotech's platform mania, here are four charts that explain what you need to know in business today.
America and the world are more divided than they have been in years -- in crude oil prices.
Something to Celebrate
U.S. stock records have soaked up all of the attention, but there's been a lot more to cheer about elsewhere in the world.
Note: Indexed to 100.
Investors buying into Alnylam's share surge may be reading too much into a single drug trial’s success.
The FDA's planned nicotine cuts and other pressures mean it's change or die time for big tobacco.
And don't miss Marcus Ashworth on Pennon's work of interest rate management art: "On Monday it successfully bought back most of its 300 million pounds ($405.7 million) of 6.75 percent perpetual bonds. It also issued the same amount of perpetual bonds with a much lower coupon, at 2.875 percent. Corporate nirvana. The lack of a credit rating paled in significance to the allure of lending to a borrower from a safe business with a steady cash flow. In fact initial price talk was for a coupon of about 3.25 percent, but the company was able to get something smaller. The price has since risen above par, and the yield is now about 2.6 percent. For an unsecured bond that technically never has to be redeemed, that's not a lot. But these are the times we live in."
This column does not necessarily reflect the opinion of Bloomberg LP and its owners.